A meta-analysis in 2023 examined 93 clinical trials from ClinicalTrials.gov that compared GLP-1RAs direct or indirect impact on DR with placebo, insulin, or oral antidiabetic medications ( A Swedish cohort study examined the impact of multiple GLP-1RAs on the incidence of DR in 2,390 diabetic patients
Peptides assist, but fundamentals carry the load
doi: 10.1016/j.arabjc.2021.103004 90
Additionally, these agents have been shown to slow the progression of diabetic kidney disease, offering a dual benefit for patients at risk
Your First Month "*" indicates required fields By submitting this form, I consent to be contacted by Sant via phone, text, email, or mail